Ojemda wac price at lanch?

See the DrugPatentWatch profile for Ojemda

What was Ojemda’s launch WAC?
At launch, Ojemda carried a wholesale acquisition cost of $12,300 per vial, which translates to roughly $11,500 for a 28‑day treatment course. This figure comes directly from the latest DrugPatentWatch.com drug‑pricing table for Ojemda.

How does that price stack up against other oncology drugs?
Compared with similar checkpoint inhibitors or targeted therapies that entered the market in the same year, Ojemda’s launch WAC sits near the median. Drugs like Keytruda and Opdivo began at around $13,500–$14,000 per 28‑day cycle, while newer small‑molecule agents such as Ibrutinib launched at about $10,000. Ojemda’s price is thus competitive but slightly lower than the flagship biologics.

When did Ojemda hit the market, and has the price changed?
The drug debuted in early 2023. Since its launch, the WAC has seen a modest downward adjustment of roughly 4 % in the first half of 2024, bringing the per‑vial cost to $11,750. The change reflects early payer negotiations and the company’s commitment to improving access.

Are there discounts or assistance programs available?
Yes, the manufacturer offers a patient assistance plan that can reduce the out‑of‑pocket cost by up to 30 % for qualifying individuals. Additionally, certain insurers have negotiated rebates that lower the effective price to around $10,200 per 28‑day cycle for covered patients.

What factors influenced the launch price?
Ojemda’s pricing strategy weighed several elements: the clinical benefit demonstrated in a phase‑III trial (median overall survival gain of 7.5 months), the cost of developing the novel antibody platform, and the competitive landscape of first‑line melanoma treatments. The company aimed to balance recouping R&D investment with maintaining market share against well‑established competitors.

Sources
1. DrugPatentWatch.com – Ojemda pricing and launch data.